Company Focus
Astellas Pharma
Latest Astellas Pharma News
Biotechnology
Japanese drug major Astellas Pharma has signed a memorandum of understanding with the Korea Institute of Startup and Entrepreneurship Development (KISED) to offer its open innovation resources to help South Korean biotech companies branch out overseas. 18 July 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Astellas Pharma
Biotechnology
Pilatus Biosciences, a US biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced a clinical trial collaboration with Swiss pharma giant Roche. 14 August 2025
Pharmaceutical
China-based RNA therapeutics developer Ribopeutic has raised close to 100 million yuan ($13.9 million) in pre-A financing, with Tasly Holding Group and Pan-Lin Asset Management leading the round. 14 August 2025
Biotechnology
Maryland, USA-based biotech MacroGenics announced that effective as of August 13, 2025, Eric Risser has been appointed president, chief executive (CEO) and to the board of directors. 14 August 2025
Biotechnology
US biotech Vedanta Biosciences has abandoned development of its ulcerative colitis candidate VE202 after the bacterial cocktail failed to outperform placebo in a mid-stage trial. 14 August 2025
Pharmaceutical
Danish CNS specialist Lundbeck has reported revenue grew 14% at constant exchange rates (CER), plus 14% DKK, to 12,258 million kroner ($1,915 million) in the first six months of 2025. Growth in the USA and Europe was the driver of this strong performance. 14 August 2025
Biotechnology
Sino-American biotech BeOne Medicines has announced financial results from the second quarter of 2025. 13 August 2025
Biotechnology
Texas, USA-based clinical-stage biotech Gameto, a clinical-stage biotechnology company developing stem cell-derived therapies for reproductive health, has announced the completion of a $44 million Series C financing. 13 August 2025
Biotechnology
Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and commercialize the US firm’s KRAS G12D inhibitor. 12 August 2025
Biotechnology
US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 clinical trial (also known as KEYNOTE-905). 12 August 2025
Biotechnology
US biotech Rezo Therapeutics today announced the appointment of Derek Hicks as its chief executive (CEO). 12 August 2025
Latest In Brief for Astellas Pharma
Pharmaceutical
Japan’s Mochida Pharmaceutical has announced that Lialda (mesalazine 600mg)the will be launched on September 8, 2025, as the NHI (National Health Insurance) Drug Price was listed on August 14, 2025. 18 August 2025
Latest Relevant Ones To Watch News
Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate deupirfenidone (LYT-100). The US Food and Drug Administration (FDA) granted approval for Insmed’s Brinsupri (brensocatib) for the treatment of a chronic inflammatory lung condition. Last week also saw US biotech Sarepta Therapeutics selling 9.3 million shares in Arrowhead, raising around $174 million, and transferring around $50 million to Arrowhead. Basilea in-licensed rights to Venatorx’ urinary tract infection candidate ceftibuten-ledaborbactam etzadroxil. 17 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze